Proto Labs
PRLBNYSEUSD
- Source valuation snapshot. Not a live recalculation.
- Latest filed annual earnings; price snapshot date unavailable. Not forward P/E.
- Diluted earnings per share from the latest filed annual.
- $67.93 Prior regular-session close from the quote source.
- $68.65–$70.33 Regular-session low and high so far today.
- 241.7K Regular-session shares traded · Nov 11, 4:00 PM ET.
- Not yet confirmed The company has not confirmed its next report date. Reported quarters are available in the chart’s Earnings view.
- $46.07–$99.96 52-week trading low and high returned by the quote source.
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
The core investment thesis
Own PRLB if speed and quoting advantages translate into renewed profitable growth, not just stable niche economics.
PRLB price history
Loading recent earnings…
Investment thesis
What must happen next
Engineers and procurement teams continue to value Proto Labs’ rapid custom-parts workflow enough that demand converts into profitable orders rather than leaking to lower-priced marketplaces or local shops.HoldingMateriality: High
GAAP annual revenue increased from $500.9 million in FY2024 to $533.1 million in FY2025, indicating renewed order conversion after a flat FY2023-FY2024 period. If the speed advantage holds, revenue can grow without a price war; if it fades, Proto Labs becomes a slower-growth job shop with weaker pricing power.
Watch: Xometry or Fictiv materially narrows lead-time and manufacturability-feedback gaps while undercutting Proto Labs on price.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual revenue increased from $500.9 million in FY2024 to $533.1 million in FY2025, indicating renewed order conversion after a.
Open source ↗Proto Labs’ combination of process expertise, manufacturing breadth, and rapid fulfillment preserves pricing power, so growth does not require gross-margin sacrifice.StrengtheningMateriality: High
GAAP annual gross profit rose from $223.2 million in FY2024 to $237.1 million in FY2025. Gross margin is the clearest test of whether Proto Labs is selling differentiated speed or merely buying volume with lower prices.
Watch: Marketplace competitors make custom-part pricing transparent enough that customers route standard jobs to the lowest bidder.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual gross profit rose from $223.2 million in FY2024 to $237.1 million in FY2025.
Open source ↗The self-service quoting and automated manufacturing model should allow incremental demand to produce operating leverage, but the evidence is not yet strong enough to prove a durable margin inflection.HoldingMateriality: Medium
GAAP annual operating income improved from $19.9 million in FY2024 to $25.1 million in FY2025. The equity upside depends on Proto Labs becoming more than a steady gross-margin business; operating leverage is what turns revenue recovery into per-share value.
Watch: More orders require manual engineering support, sales involvement, or quality intervention, weakening the automation thesis.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual operating income improved from $19.9 million in FY2024 to $25.1 million in FY2025.
Open source ↗The short-cycle custom manufacturing model and working-capital discipline continue to convert accounting profit into cash that can fund investment without stressing the balance sheet.StrengtheningMateriality: Medium
GAAP annual operating cash flow was $74.5 million in FY2025 versus GAAP annual net income of $21.2 million. Strong cash conversion gives management room to reinvest, repurchase shares, or withstand manufacturing downturns; weak conversion would make modest earnings less valuable.
Watch: A shift toward larger production jobs lengthens receivables cycles or requires more inventory, reducing working-capital efficiency.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual operating cash flow was $74.5 million in FY2025 versus GAAP annual net income of $21.2 million.
Open source ↗A cash-rich, low-liability balance sheet gives Proto Labs the option to invest through cyclical weakness and avoid forced financing while the growth thesis is being tested.StrengtheningMateriality: Medium
Cash was $110.8 million at FY2025 year-end, up from $89.1 million at FY2024 year-end and $56.6 million at FY2022 year-end. Balance-sheet strength lowers existential risk and increases management’s strategic flexibility, but it does not by itself solve the growth problem.
Watch: Management uses cash for a large acquisition that fails to improve customer reach, manufacturing breadth, or margins.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Cash was $110.8 million at FY2025 year-end, up from $89.1 million at FY2024 year-end and $56.6 million at FY2022 year-end.
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
Engineers and procurement teams continue to value Proto Labs’ rapid custom-parts workflow enough that demand converts into profitable orders rather than leaking to lower-priced marketplaces or local shops. If the speed advantage holds, revenue can grow without a price war; if it fades, Proto Labs becomes a slower-growth job shop with weaker pricing power.
Proto Labs’ combination of process expertise, manufacturing breadth, and rapid fulfillment preserves pricing power, so growth does not require gross-margin sacrifice. Gross margin is the clearest test of whether Proto Labs is selling differentiated speed or merely buying volume with lower prices.
The self-service quoting and automated manufacturing model should allow incremental demand to produce operating leverage, but the evidence is not yet strong enough to prove a durable margin inflection. The equity upside depends on Proto Labs becoming more than a steady gross-margin business; operating leverage is what turns revenue recovery into per-share value.
The short-cycle custom manufacturing model and working-capital discipline continue to convert accounting profit into cash that can fund investment without stressing the balance sheet. Strong cash conversion gives management room to reinvest, repurchase shares, or withstand manufacturing downturns; weak conversion would make modest earnings less valuable.
A cash-rich, low-liability balance sheet gives Proto Labs the option to invest through cyclical weakness and avoid forced financing while the growth thesis is being tested. Balance-sheet strength lowers existential risk and increases management’s strategic flexibility, but it does not by itself solve the growth problem.
All standing thesis claims
Original report summary
speed and quoting advantages translate into renewed profitable growth, not just stable niche economics.
Bull case and bear case
Bull case and bear case for Proto Labs
Where the evidence on Proto Labs stands: Holding on the latest evidence (Oct 13, 2026). Of its 5 thesis points, 3 strengthening and 2 holding.
Bull case: what the evidence supports
Engineers and procurement teams continue to value Proto Labs’ rapid custom-parts workflow enough that demand converts into profitable orders rather than leaking to lower-priced marketplaces or local shops.
Proto Labs’ combination of process expertise, manufacturing breadth, and rapid fulfillment preserves pricing power, so growth does not require gross-margin sacrifice.
The self-service quoting and automated manufacturing model should allow incremental demand to produce operating leverage, but the evidence is not yet strong enough to prove a durable margin inflection.
The short-cycle custom manufacturing model and working-capital discipline continue to convert accounting profit into cash that can fund investment without stressing the balance sheet.
A cash-rich, low-liability balance sheet gives Proto Labs the option to invest through cyclical weakness and avoid forced financing while the growth thesis is being tested.
Bear case: what would count against it
Xometry or Fictiv materially narrows lead-time and manufacturability-feedback gaps while undercutting Proto Labs on price.
Marketplace competitors make custom-part pricing transparent enough that customers route standard jobs to the lowest bidder.
More orders require manual engineering support, sales involvement, or quality intervention, weakening the automation thesis.
Thesis-Break Engine
Thesis-break watch · Proto Labs
No break has crossed Proto Labs’s thesis. Its break conditions are checked against every new filing as it lands.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
- MixedRegulation FD disclosure.
Proto Labs filed an SEC 8-K on 2026-08-24: Regulation FD disclosure. It is a dated development that tests the current thesis.
- MixedReported results of operations (earnings release).
Proto Labs filed an SEC 8-K on 2026-07-31: Reported results of operations (earnings release). It is a dated development that tests the current thesis.
- MixedDirector or principal officer change.
Proto Labs filed an SEC 8-K on 2026-05-20: Director or principal officer change. It is a dated development that tests the current thesis.
Risks / falsifiers
What could break the thesis
- Xometry or Fictiv materially narrows lead-time and manufacturability-feedback gaps while undercutting Proto Labs on price.
- Marketplace competitors make custom-part pricing transparent enough that customers route standard jobs to the lowest bidder.
- More orders require manual engineering support, sales involvement, or quality intervention, weakening the automation thesis.
- A shift toward larger production jobs lengthens receivables cycles or requires more inventory, reducing working-capital efficiency.
- Management uses cash for a large acquisition that fails to improve customer reach, manufacturing breadth, or margins.
PRLB news
Loading headlines…
Financial statements
PRLB income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.
PRLB: quick answers
- Have members of Congress traded PRLB?
- 5 trades in PRLB have been disclosed under the STOCK Act by members of Congress, the President or senior officials, none in reports made public in the last 90 days. Every disclosed PRLB trade
- Which well-known investors own PRLB?
- 1 of the 37 well-known funds tracked here reported PRLB shares in their latest 13F filing. By share of the fund's portfolio: ARK Investment Management (Cathie Wood), 0.0%. Fund portfolios
PRLB in well-known investors’ portfolios
1 of 37 funds reported PRLB shares in their latest 13F filing. A 13F shows quarter-end positions and arrives up to 45 days later.
| Fund | Of its portfolio | Value | Change | Quarter |
|---|---|---|---|---|
| Cathie WoodARK Investment Management | 0.02% | $2.9M | −22.5% | Q2 2026 |
